Semafore Pharmaceuticals Announces Presentation Highlighting Activity of Multi-Kinase, PI3K/mTOR Inhibitor SF1126 at 2011 AACR Annual Meeting

[Guest guest]

BlankSemafore Pharmaceuticals Announces Presentation Highlighting Activity of

Multi-Kinase, PI3K/mTOR Inhibitor SF1126 at 2011 AACR Annual Meeting

Press Release

Phase 1 Study in B-Cell Malignancies in Combination With Rituximab Ongoing

INDIANAPOLIS, March 9, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals

announced today that preclinical data in B-cell malignancies for the company's

lead product candidate SF1126 will be presented at the 102nd Annual Meeting of

the American Association for Cancer Research (AACR), to be held April 2-6, 2011,

in Orlando, FL. SF1126 is a novel peptidic prodrug that converts to LY294002,

one of the most widely studied small molecule inhibitors of all Class I

phosphatidylinositol 3-kinase (PI3K) isoforms, mammalian target of rapamycin

(mTOR), the proto-oncogene PIM-1, and other cancer-specific kinase targets.

The preclinical studies being presented serve as translational support for

ongoing clinical investigation of SF1126 alone and in combination with rituximab

in certain B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL),

indolent non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and

mantle cell lymphoma (MCL), which is currently being conducted at the Arizona

Cancer Center. The preclinical studies being presented also include a

head-to-head comparison between SF1126 and the clinical-stage, delta

isoform-selective PI3K inhibitor (CAL-101) with regard to inducing apoptosis and

inhibiting cell proliferation in DLBCL cell lines.

Full story

http://www.globenewswire.com/newsroom/news.html?d=215776